AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33029899 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of ingested and excreted calories using bomb calorimetry over 3 days.
Number of subjects: 0
Study 33029899 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight of stool samples during dietary intervention.
Number of subjects: 0
Study 33029899 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool calories per gram for pellets.
Number of subjects: 0
Study 33029899 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool measurement of kilocalories per gram.
Number of subjects: 0
Study 33030436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively healthy older experimental participants
Number of subjects: 13
Study 33030436 — intervention group
Group type: COMPARATOR
Intervention: Cognitively healthy older control participants
Number of subjects: 13
Study 33030436 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with dementia
Number of subjects: 13
Study 33030436 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire outcomes for usability and immersion
Number of subjects: 13
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility t-test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: 505 agility test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg hop for distance test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-hop test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement jump test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-m sprint test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-m sprint test
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuck jump assessment (TJA)
Number of subjects: 115
Study 33030610 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop vertical jump (DVJ)
Number of subjects: 115
Study 33030704 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (weight-based dosing regimen)
Number of subjects: 0
Study 33030848 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 IC+ (ventana SP142 assay)
Number of subjects: 670
Study 33030848 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 IC+ prevalence by anatomic location
Number of subjects: 670
Study 33030848 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 IC status agreement
Number of subjects: 670
Study 33030871 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical failure defined as apical descent greater than one third of the total vaginal length, anterior or posterior vaginal wall past the hymen, subsequent surgery or bothersome vaginal bulge.
Number of subjects: 659
Study 33030871 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening Pelvic Organ Prolapse Distress Inventory score.
Number of subjects: 659
Study 33030871 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening Urinary Distress Inventory score.
Number of subjects: 659
Study 33030871 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening Colorectal-Anal Distress Inventory score.
Number of subjects: 659
Study 33030975 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4 measurement
Number of subjects: 143
Study 33031046 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Behavioral Activation, 50-minute weekly sessions for 4 weeks using a VR headset
Number of subjects: 1
Study 33031046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report rating scales for acceptability, tolerability, and depression symptoms
Number of subjects: 1
Study 33031354 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Assisted Severe Febrile Illness Therapy
Number of subjects: 107
Study 33031412 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior spinal fusion (PSF) in AIS subjects
Number of subjects: 30
Study 33031412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 33031412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIS and control subjects
Number of subjects: 30
Study 33031542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of venetoclax plus ibrutinib for ≥12 months
Number of subjects: 0
Study 33031789 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month DAPT
Number of subjects: 3652
Study 33031789 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT
Number of subjects: 3652
Study 33031789 — intervention group
Group type: COMPARATOR
Intervention: Historical control from XIENCE V USA study
Number of subjects: 3652
Study 33031809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-Linking treatment for fungal keratitis
Number of subjects: 0
Study 33031809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33031861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions
Number of subjects: 134
Study 33031955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg (up to 800 mg) as one intravenous administration, with a second optional administration after 12 hours.
Number of subjects: 330
Study 33031971 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary progressive aphasia variants (nonfluent, logopenic, semantic)
Number of subjects: 0
Study 33031971 — intervention group
Group type: EXPERIMENTAL
Intervention: Logopenic and semantic variants
Number of subjects: 0
Study 33031977 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS patients
Number of subjects: 22
Study 33031977 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 33031977 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS patients (excluding those with frontotemporal dementia)
Number of subjects: 22
Study 33032328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal vitamins/multivitamins
Number of subjects: 2164
Study 33032328 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications
Number of subjects: 2164
Study 33032328 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall supplement intake
Number of subjects: 2164
Study 33032328 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall medication use
Number of subjects: 2164
Study 33032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical management with follow-up imaging
Number of subjects: 72
Study 33032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow status (time-varying)
Number of subjects: 72
Study 33032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean blood pressure assessment
Number of subjects: 72
Study 33032536 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-GAN generated synthetic MRI images
Number of subjects: 303
Study 33032536 — intervention group
Group type: COMPARATOR
Intervention: U-Net trained on patient data
Number of subjects: 303
Study 33032571 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 1203
Study 33032571 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities associated with depressive symptoms
Number of subjects: 1203
Study 33032571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular medication of ticagrelor
Number of subjects: 1203
Study 33032615 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger gaiting during tactile manipulation of a cuboid using a digital data glove with 29 sensors.
Number of subjects: 22
Study 33032615 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger gaiting as a mechanism underlying the manipulation task.
Number of subjects: 22
Study 33032662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ+NfL+
Number of subjects: 452
Study 33032662 — intervention group
Group type: COMPARATOR
Intervention: Control group (multidomain interventions, omega-3 supplementation, multidomain plus omega-3 supplementation)
Number of subjects: 452
Study 33032708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate after 8 hours (L2)
Number of subjects: 671
Study 33032708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance (LC)
Number of subjects: 671
Study 33032708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lactate (L1)
Number of subjects: 671
Study 33032892 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC)
Number of subjects: 50
Study 33033006 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI mapping of tumour deposits (TDs)
Number of subjects: 100
Study 33033101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 12
Study 33033101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 150 mg
Number of subjects: 12
Study 33033101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 75 mg
Number of subjects: 12
Study 33033101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (all doses)
Number of subjects: 12
Study 33033102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast algorithms as per 2015 European Society of Cardiology guidelines
Number of subjects: 2525
Study 33033149 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30 kg·m²)
Number of subjects: 203
Study 33033149 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight patients (BMI <25 kg·m²)
Number of subjects: 203
Study 33033150 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic two-dimensional shear-wave ultrasound elastography
Number of subjects: 354
Study 33033800 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 20
Study 33033800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33033885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 1144
Study 33033885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144
Study 33034006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib modified-release (MR) 11 mg once-daily (QD)
Number of subjects: 0
Study 33034006 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib immediate-release (IR) 5 mg twice-daily (BID)
Number of subjects: 0
Study 33034050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CRYM expression levels in PCa patients
Number of subjects: 0
Study 33034050 — intervention group
Group type: EXPERIMENTAL
Intervention: CRYM
Number of subjects: 0
Study 33034194 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90011
Number of subjects: 0
Study 33034295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravital microscopy (IVM) during surgical resection
Number of subjects: 20
Study 33034295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravital microscopy (IVM) during administration of vasopressors or fluid boluses
Number of subjects: 20
Study 33034567 — intervention group
Group type: EXPERIMENTAL
Intervention: emma app (Ecological Momentary Assessment and Intervention)
Number of subjects: 14
Study 33034567 — intervention group
Group type: EXPERIMENTAL
Intervention: emma app (Safety Plan Modules)
Number of subjects: 14
Study 33034806 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 654
Study 33034806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 654
Study 33034806 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 654
Study 33034806 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 654
Study 33034806 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of TAT adoption
Number of subjects: 654
Study 33034806 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of DAT adoption
Number of subjects: 654
Study 33034839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (350 mg/m2) administered following radiotherapy in 28-day cycles
Number of subjects: 10
Study 33034900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment (ice pack or cold gel pad)
Number of subjects: 1233
Study 33034900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment (cold gel pad) + compression
Number of subjects: 1233
Study 33034900 — intervention group
Group type: COMPARATOR
Intervention: Cooling treatment (ice pack)
Number of subjects: 1233
Study 33035067 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Parent Training for Irritability and Disruptive Behavior
Number of subjects: 0
Study 33035138 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 1260
Study 33035138 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 1260
Study 33035138 — intervention group
Group type: COMPARATOR
Intervention: Voiding spontaneously
Number of subjects: 1260
Study 33035138 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 physical scores
Number of subjects: 1260
Study 33035138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminished hand function
Number of subjects: 1260
Study 33035138 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 1260
Study 33035333 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel), an anti-CD19 CAR T-cell therapy
Number of subjects: 0
Study 33035333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid CAR T-cell expansion
Number of subjects: 0
Study 33035333 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of CD8 and CCR7+CD45RA+ T cells infused
Number of subjects: 0
Study 33035333 — intervention group
Group type: EXPERIMENTAL
Intervention: Host systemic inflammation
Number of subjects: 0
Study 33035333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical covariates (ECOG performance status, age, disease subtype, disease stage, IPI score)
Number of subjects: 0
Study 33036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention consisting of 10-min exposure via a headset with sceneries, background meditation music, and breathing exercises.
Number of subjects: 108
Study 33036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 108
Study 33036564 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminex xTAG® multiplex PCR testing for enteric pathogens
Number of subjects: 269
Study 33037018 — intervention group
Group type: EXPERIMENTAL
Intervention: UroCAD (Urine Exfoliated Cells Copy Number Aberration Detector)
Number of subjects: 190
Study 33037018 — intervention group
Group type: COMPARATOR
Intervention: Cytology tests
Number of subjects: 190
Study 33037105 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib (oral) and 2.0 mg/m² topotecan
Number of subjects: 19
Study 33037117 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MEDI9197 0.005-0.055 mg
Number of subjects: 52
Study 33037117 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MEDI9197 0.012 mg plus durvalumab 1500 mg
Number of subjects: 52
Study 33037117 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MEDI9197
Number of subjects: 52
Study 33037135 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 905711, a novel tetravalent bispecific antibody targeting TRAILR2 and CDH17
Number of subjects: 0
Study 33037746 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent transplant care intervention (HKTP)
Number of subjects: 44
Study 33037874 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliCare for College Students app
Number of subjects: 20
Study 33038155 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light at 675 nm
Number of subjects: 30
Study 33038155 — intervention group
Group type: EXPERIMENTAL
Intervention: Far red light at 750 nm
Number of subjects: 30
Study 33038155 — intervention group
Group type: EXPERIMENTAL
Intervention: Far red light at 800 nm
Number of subjects: 30
Study 33038155 — intervention group
Group type: COMPARATOR
Intervention: Standard cobalt blue light
Number of subjects: 30
Study 33038155 — intervention group
Group type: EXPERIMENTAL
Intervention: Light source at 750 and 800 nm
Number of subjects: 30
Study 33038188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Number of subjects: 96
Study 33038190 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle.
Number of subjects: 132
Study 33038223 — intervention group
Group type: EXPERIMENTAL
Intervention: HARPOON beating heart mitral valve repair system
Number of subjects: 65
Study 33038231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent syncope
Number of subjects: 1790
Study 33038231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac syncope
Number of subjects: 1790
Study 33038231 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncope with unknown aetiology
Number of subjects: 1790
Study 33038231 — intervention group
Group type: EXPERIMENTAL
Intervention: >3 previous episodes of syncope
Number of subjects: 1790
Study 33038277 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with nab-paclitaxel and gemcitabine
Number of subjects: 600
Study 33038286 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg daily
Number of subjects: 562
Study 33038286 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg daily
Number of subjects: 562
Study 33038286 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg daily (patients meeting criteria for dose reduction)
Number of subjects: 562
Study 33038286 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg daily (patients meeting criteria for dose reduction)
Number of subjects: 562
Study 33038344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (FOLE) 1 g/kg/d
Number of subjects: 262
Study 33038344 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil intravenous lipid emulsion (SOLE) ≤3 g/kg/d
Number of subjects: 262
Study 33038346 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate anxiolytics tested in human models of anxiety using anxiety-potentiated startle.
Number of subjects: 0
Study 33038346 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-potentiated startle model.
Number of subjects: 0
Study 33038902 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger attacks (≥9 in the past month)
Number of subjects: 293
Study 33038902 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger attacks at baseline
Number of subjects: 293
Study 33038902 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with anger attacks
Number of subjects: 293
Study 33038902 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with aggressive behaviors
Number of subjects: 293
Study 33038902 — intervention group
Group type: COMPARATOR
Intervention: Participants without anger attacks
Number of subjects: 293
Study 33038933 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS-29
Number of subjects: 1500
Study 33038933 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact Stratification Score (ISS) based on PROMIS-29 items
Number of subjects: 1500
Study 33038933 — intervention group
Group type: COMPARATOR
Intervention: MTurk data collection
Number of subjects: 1500
Study 33039202 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 73
Study 33039202 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity support planning
Number of subjects: 73
Study 33039202 — intervention group
Group type: EXPERIMENTAL
Intervention: Session on using support
Number of subjects: 73
Study 33039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria combined with spleen stiffness measurement (cut-off 46 kPa)
Number of subjects: 341
Study 33039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria
Number of subjects: 341
Study 33039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen stiffness measurement (cut-off ≤46.0 kPa)
Number of subjects: 341
Study 33039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (Baveno VI criteria and spleen stiffness measurement cut-off ≤46 kPa)
Number of subjects: 341
Study 33039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Baveno VI criteria
Number of subjects: 341
Study 33039474 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33039599 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 90 mg daily for 7 days, then escalated to 180 mg daily
Number of subjects: 20
Study 33039599 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 20
Study 33039812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal oxaliplatin delivered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) at a dose of 90 mg/m
Number of subjects: 10
Study 33039989 — intervention group
Group type: EXPERIMENTAL
Intervention: New MDR-TB regimens containing bedaquiline, pretomanid, and linezolid
Number of subjects: 0
Study 33039989 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for MDR-TB patients
Number of subjects: 0
Study 33039989 — intervention group
Group type: EXPERIMENTAL
Intervention: New MDR-TB regimens
Number of subjects: 0
Study 33040013 — intervention group
Group type: EXPERIMENTAL
Intervention: VitalScan MCG (Creavo Medical Technologies, UK)
Number of subjects: 270
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hARF (PaO2/FiO2 <100 mm Hg)
Number of subjects: 412
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hARF (PaO2/FiO2 101-200 mm Hg)
Number of subjects: 412
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hARF (PaO2/FiO2 201-300 mm Hg)
Number of subjects: 412
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 412
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: PaO2/FiO2 ratio ≤200 mm Hg
Number of subjects: 412
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory failure at admission
Number of subjects: 412
Study 33040020 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe impairment in PaO2/FiO2
Number of subjects: 412
Study 33040383 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipod Insulin Management System
Number of subjects: 286